Home > Compound List > Product Information
Fluticasone Propionate_Molecular_structure_CAS_80474-14-2)
Click picture or here to close

Fluticasone Propionate

Catalog No. DB00588 Name DrugBank
CAS Number 80474-14-2 Website http://www.ualberta.ca/
M. F. C25H31F3O5S Telephone (780) 492-3111
M. W. 500.5708496 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 470

SYNONYMS

IUPAC name
(1R,2S,8S,10S,11S,13R,14R,15S,17S)-1,8-difluoro-14-{[(fluoromethyl)sulfanyl]carbonyl}-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate
IUPAC Traditional name
fluticasone propionate
Brand Name
Flovent
Flunase
Flovent Diskus 100
Advair Diskus 250/50
Advair Diskus 100/50
Advair Diskus 500/50
Cutivate
Flixonase
Flixotide
Flonase
Flovent Diskus 250
Flovent Diskus 50
Flovent HFA
Advair Diskus
Synonyms
fluticasone propionate

DATABASE IDS

PubChem SID 46506140
CAS Number 80474-14-2
PubChem CID 444036

PROPERTIES

Hydrophobicity(logP) 3.4
Solubility 0.51 mg/L (insoluble)

DETAILS

Description (English)
Item Information
Drug Groups approved; investigational
Description Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma.
Indication For the maintenance treatment of asthma as prophylactic therapy and for patients requiring oral corticosteroid therapy for asthma.
Pharmacology Fluticasone propionate, a medium-potency synthetic corticosteroid, is used topically to relieve inflammatory and pruritic symptoms of dermatoses and psoriasis, intranasally to manage symptoms of allergic and non-allergic rhinitis, and orally for the treatment of asthma.
Affected Organisms
Humans and other mammals
Biotransformation Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothioate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17-(beta)-carboxylic acid metabolite, the only known metabolite detected in man.
Absorption The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier.
Half Life 10 hours
Protein Binding 91%
Distribution * 2.3 to 16.7 L/kg
Clearance * 1093 mL/min
External Links
RxList
Drugs.com

REFERENCES